STOCKHOLM – November 9, 2017. Karolinska Development today announces that the company will receive 140,149 shares in Pharmanest AB. Furthermore, the company will receive 11,527 shares via KCIF Co-Investment Fund. In total, this corresponds to an ownership of 10,4 percent in Pharmanest. Pharmanest is one of the companies covered by Karolinska Development’s earn out-agreements. The transaction requires approval at the general meeting at Pharmanest.

Pharmanest develops a new and innovative treatment of pain in conjunction with gynaecological procedures, based on its unique technology platform SHACT. The company recently entered a license agreement with the pharmaceutical company Gedeon Richter Plc. This agreement gives Gedeon Richter the right to commercialize Pharmanest’s SHACT technology in Europe, Latin America and other specific geographies.

Karolinska Development will receive 140,149 shares in Pharmanest. Moreover, Karolinska development will receive 11,527 shares via KCIF Co-Investment Fund KB, a holding company jointly owned by the European Investment Fund and Karolinska Development.

“The ownership in Pharmanest AB has a positive impact on our overall portfolio value and we look forward to following the company’s future development. This is yet another confirmation of the value in the earn-out agreements we have signed in conjunction with divestments”, says Viktor Drvota, CEO, Karolinska Development.
For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 2.45 pm CET on 9 of November 2017. 

The agreed Acquisition of ProSang company strengthens CSAM’s position as the leading provider of specialized solutions in the Nordic eHealth Market.

OSLO, Norway

(November 1st , 2017) – CSAM Health AS announced today that it has signed an agreement to acquire the Swedish company Databyrån AB, makers of ProSang. With this acquisition, CSAM adds an exciting new specialized product area to its leading portfolio of eHealth niche solutions in the Nordics.

ProSang is an advanced Laboratory Information Management System (LIMS) that simplifies the entire management of blood – from blood donor call–up to transfusion. Since its inception in 1965, Databyrån AB has grown to achieve a leading market position within the Nordics. Today, more than 180 blood centres and several clinical immunology and transplantation departments use ProSang.

“Databyrån AB has established loyal and satisfied user groups in many countries, and I am incredibly impressed by what their team has accomplished with ProSang,” said Sverre Flatby, CEO of CSAM. “We are proud that the owners of ProSang have chosen to join the CSAM team, and we look forward to welcoming them and working together to secure further growth and export.”

“To continue the journey towards our ambitious vision, I am confident that CSAM is the best home for ProSang, Databyrån’s employees, and our customers,” said Daniel Wiman, Press release November 1st, 2017

Chairman of Databyrån AB. “Today’s agreement ensures that our employees can continue working as a specialized team, while benefitting from the shared services CSAM provides, and strengthening our sales and development capabilities.” The Databyrån AB transaction reinforces CSAM’s focus on accelerating growth through strategic acquisitions, strengthening the company’s portfolio of niche products and their leadership position in the Nordic eHealth market.

About CSAM Health AS

CSAM is a privately-owned eHealth company delivering software solutions that enable healthcare providers to access relevant clinical information at the point of care. CSAM’s headquarters are located in Oslo, Norway, with local offices in Stockholm, Gothenburg, Helsinki, Oulu, Tampere, and London. The company also has a fully owned software engineering subsidiary in the Philippines. CSAM has established itself as a leading Nordic niche player in the specialized eHealth market, with a unique blend of best-in-class innovative technology and outstanding human skills. Backed by strong financial owners, CSAM aspires to achieve continued growth both organically and through selected mergers and acquisitions.

For more information, visit csamhealth.com

About Databyrån AB

Databyrån AB is based in Sweden and serves healthcare professionals across the Nordics. Founded in 1965, the company is a leader in software development for transfusion medicine, developing strong relationships with its users. Databyrån AB’s clients span the fields of transfusion medicine, immunology, transplantation immunology, and tissue management.

For more information, visit databyran.se and prosang.com

For more information, please contact:

Daniel Wiman

Chairman, Databyrån AB

+46 70-482 77 57

daniel.wiman@databyran.se

Sverre Flatby

Group CEO, CSAM Health AS

+47 9159 9159

sverre.flatby@csamhealth.com

Sales of Healthcare division tripled in space of two years
•    Focus on semiconductor industry business
•    Objective: Expansion of market position in the US

Frankfurt am Main, Germany, 3 November 2017. Cleanpart Group GmbH, a company in the Deutschen Beteiligungs AG (DBAG) portfolio, will in future focus on providing services for the semiconductor industry and is therefore selling its healthcare business. The buyer is VAMED, a hospital services provider, majority owned by Fresenius SE & Co. KGaA. In April 2015, DBAG invested in Cleanpart alongside DBAG Fund VI for which it provides consultation; the fund had acquired the company as part of the company’s successor solution. The partial sale has been completed with an attractive valuation; it reflects the company’s development, the good course of business in the last two years and the positive outlook for the coming years. The valuation is above that of the investment value in the last interim report published by DBAG. The rise in value has already been taken into consideration in the current DBAG forecast for the 2016/2017 financial year (30 September, preliminary figures will be published on 23 November 2017).

Cleanpart Group (www.cleanpart.com) generated over 20 percent of its revenues with its healthcare business. The company prepared reusable medical products for hospitals as an external service provider. Services included manual and mechanical instrument cleaning and sterilisation as well as repair and maintenance. Cleanpart also provided hospital operators with planning and construction consultation as well as advice for the operation of central sterilisation. The healthcare business has shown very positive development over the last two years: revenues have trebled, internally, thanks to measures to broaden the service portfolio, and externally, thanks to the acquisition of a competitor. Investments were also made in a new site to expand capacity.

“The market environment in our core business – the semiconductor industry – is excellent and offers great growth opportunities with existing and new customers,” explains Dr Udo Nothelfer, Chairman of the Cleanpart Management Board. “We want to make the most of these opportunities by focussing on our core business.” This is due to the sustained high level of investment in the development of new semiconductor manufacturing facilities and the good capacity utilisation levels of existing production facilities. Cleanpart maintains process-critical components in machines that are primarily used in the production of logic chips, memory chips, etc. Since these components become contaminated and wear out, they must be regularly decontaminated, cleaned and coated to ensure that they meet the extreme purity and performance requirements in the production processes of chip manufacturers. This also extends the components’ useful lives.

Torsten Grede, Spokesman of the DBAG Board of Management, commented on the partial sale: “Cleanpart has a solid foundation and a leading market position in Europe – we will now assist the company’s management in expanding its market position in the US with a strategy based on high technological differentiation.”

AMRA and BioTelemetry Research, a leading global imaging and cardiac core lab, announced today the formation of an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials. This first-to-market partnership will advance imaging science and benefit clinical trial sponsors in several musculoskeletal and metabolic therapeutic areas.

In clinical studies, muscle and fat fractions have traditionally been measured by scanning individual organs such as the liver, or particular body regions such as the abdomen. Commonly, researchers would prefer to scan the entire body in order to learn exactly where study participants are losing or gaining muscle or fat mass. However, until now they have been constrained by prohibitive costs and insufficiently precise outcomes.

AMRA’s body composition analysis service has introduced a new and better paradigm where rapid, six-minute whole body MRI scans are transformed into precise, three dimensional-volumetric fat and muscle measurements. This standardized, automated method eliminates reader variability and reduces processing costs. With those advancements, BioTelemetry Research is able to provide clinical trial sponsors with new, high-value information to about their drug compounds’ efficacy and mechanisms of action, including the identification of previously undetectable changes within and beyond the liver.

Tommy Johansson, Chief Executive Officer of AMRA, commented, “BioTelemetry Research is the ideal core lab to help us deliver this enhanced value to clinical trial sponsors. They bring unique expertise managing the protocol complexity, site training intensity and equipment variability that are common to non-standard-of-care MRI trials.” He continued, “BioTelemetry was a leading pioneer in proton density fat fraction (PDFF) analysis, and have analysed more liver fat cases, from more sites, in more regions than any other group in industry. I am excited to see where our partnership will take us.”

BioTelemetry Research President and General Manager, Scott Satin, added, “By employing AMRA’s automated analysis, we are now able to efficiently provide more actionable data to our pharmaceutical partners. Ordinarily, a whole body MRI scan takes 10 to 15 minutes and produces hundreds of images. Prior to AMRA, such analyses were infeasible in clinical trials largely because of the time needed to label fat and muscle tissues within every image. With those challenges eliminated, we can now help sponsors assess the effects of their treatments more quickly and completely.”

CapMan Buyout press release 6 October 2017 at 11.00 a.m. EEST

CapMan Buyout to divest Oral Hammaslääkärit to Colosseum Dental Group

A group of investors led by CapMan Buyout, including funds managed by CapMan Buyout, are pleased to announce to have reached an agreement to divest Oral Hammaslääkärit Plc (“Oral”) to Colosseum Dental Group (“Colosseum”), a Swiss-based dentistry group. Financial terms of the transaction have not been disclosed.

Oral is the leading Finnish private dentistry chain with 63 clinics and sales close to EUR 100 million. During CapMan’s ownership, Oral’s revenue has increased by 15 per cent annually while EBITDA has increased by a compound annual growth rate of 19 per cent. Funds managed by CapMan acquired Oral in 2014.

Together with Oral, Colosseum is expected to have sales of around EUR 350 million and will operate more than 200 clinics in Finland, Norway, Sweden, the UK, Switzerland, Italy and Denmark, further pursuing its journey to build a leading pan-European dentistry group.

“We are very pleased with the development of Oral and the return of our investment. During our ownership, Oral has significantly expanded and completed several developments projects, especially within the digitalisation of its operations. Today, Oral is one of the most developed private dental care companies in Europe. Oral will in my mind fit very well into Colosseum Dental Group, who will continue to support the company in its future development and further build on the strengths of the business and its ongoing initiatives. It has been an honour to be part of Oral’s development, and I would like to offer my sincere thanks to the company’s management, the dental care professionals and all its employees,” says Jan Mattlin, Partner at CapMan Buyout and responsible for the investment in Oral.

“We are delighted to become part of the Colosseum Dental Group. The company has a long-term mandate to build a strong European dentistry platform. This allows us here in Finland to continue building a great local business with high quality offering for both patients and dentists. We will continue to improve oral health in Finland as we have done for the past 35 years. Oral’s strong brand will prevail in Finland and our employees and dentists will have even more opportunities to develop their know-how in the future through the opening-up of opportunities for international exchange. We see the acquisition as a very positive opportunity for our service development in the years to come”, says Martin Forss, CEO of Oral.

“With Oral we both reach a group of highly competent new colleagues, as well as gain access to forefront know-how around how to run many of our processes in a more advanced manner that we can leverage across other geographies. Our vision of modern, high quality dentistry for the benefit of patients, dentists and employees fits well with what management wants to accomplish. We are certain that the increased scale of the new company will be for the benefit of all stakeholders,” says Tomas Aubell, CEO of Colosseum.

Colosseum will continue to support management with its development of the company and Martin Forss and his team have agreed to continue to run Oral also after the transaction. The transaction is expected to close in November 2017.

For more information, please contact:
Jan Mattlin, Partner, CapMan Buyout
jan.mattlin@capman.com
+358 40 508 6406

Tomas Aubell, Chief Executive Officer, Colosseum Dental Group
tomas.aubell@colosseumdental.com
+41 79 519 55 02

Martin Forss, Chief Executive Officer, Oral Hammaslääkärit Plc
martin.forss@oral.fi
+358 40 779 6266

About CapMan
CapMan is a leading Nordic investment and specialised asset management company. As one of the Nordic private equity pioneers we have actively developed hundreds of companies and real estate and thereby created substantial value in these businesses and assets over more than 25 years. CapMan has today 110 private equity professionals and manages €2.3 billion in assets. We mainly manage the assets of our customers, the investors, but also make direct investments from our own balance sheet in areas without an active fund. Our objective is to provide attractive returns and innovative solutions to investors and value adding services to professional investment partnerships, growth-oriented companies and tenants. Our current investment strategies cover Buyout, Growth Equity, Real Estate, Russia, Credit and Infrastructure. We also have a growing service business that currently includes fundraising advisory, procurement activities and fund management.
www.capman.com
twitter.com/CapManPE

About Colosseum Dental Group
Colosseum Dental Group, a company fully owned by Jacobs Holding AG, has the ambition to become the leading European provider for dentistry services. With the acquisition of Oral, Colosseum now operates more than 200 clinics with 900 dentists across Finland, Norway, Sweden, the UK, Switzerland, Italy and Denmark with run-rate sales of approximately EUR 350 million. The group wants to provide modern, quality dentistry services for the benefit of patients, dentists, employees and shareholders alike, striving for continuous growth and excellence.
www.colosseumdental.com

About Oral Hammaslääkärit Plc
The Finnish Oral Hammaslääkärit Plc is a service company offering oral health care, with more than 1,300 professionals providing services throughout Finland. In 2016, the company’s revenue amounted to EUR 81.4 million. Oral provides dental health services at over 60 dental clinics in various locations in Finland. The dental laboratory Oral Hammaslaboratorio Oy is part of the Group.
www.oral.fi

3i Group plc (“3i”) today announces that Ponroy, a leading manufacturer of natural healthcare and cosmetics products in which 3i invested in January 2017, has acquired ERSA Group (“Aragan”), a designer and distributor of premium pharmaceutical food supplements. This acquisition will strengthen Ponroy’s presence in the pharmacy channel, which represents more than half of the food supplement market in France.

Under the leadership of Philippe Charrier, the combined group will be a leading player in the natural consumer healthcare industry in France with revenues in excess of €200m. Ponroy will benefit from Aragan’s innovative culture and Ponroy’s international presence will enable Aragan to penetrate new markets outside France.

Aragan, which employs approx. 100 staff, sells its food supplements through three brands: ARAGAN, SYNActifs and ERBALAB. The company has grown at 40% p.a. since 2012 into one of the leading players in the pharmacy channel in France, by using its innovation-led approach to develop a number of professional brands based on health and wellbeing. The combined business will become #4 in the pharmacy channel in France, with around €50m of revenues.

Remi Carnimolla, Partner & Managing Director 3i France, and Guillaume Basquin, Director 3i France, commented:

“3i is delighted to support Ponroy’s first acquisition since our investment which confirms Ponroy’s ambitious growth plans in line with the strategy we set out. Aragan is very complementary to Ponroy and we look forward to supporting the combined business to continue its international growth, further strengthen its position in the pharmacy channel in France and continue to take advantage of the rise of natural consumer healthcare which is a mega consumer trend in food and cosmetics.”

Nicolas Brodetsky, currently Aragan CEO since 2011, will lead the pharmacy business unit for the combined group. He said:

“I am delighted by this new partnership between Ponroy and Aragan and the future opportunities for both businesses. This is a key step in our development. New and exciting challenges are ahead of us and I am delighted to join Philippe Charrier and his team to establish a leader in the food supplement market with high potential for international growth. I would like to thank Calcium Capital for the last 4 years of partnership, which have enabled us to strengthen our development model.”

-Ends-

For further information, contact:

3i Group plc
Silvia Santoro
Investor enquiries
Tel: +44 20 7975 3258
Email: silvia.santoro@3i.com